Evidence map›Paper›PMID 32429772›Full record

ArticleJournal of psychoactive drugs

Public Health and Medicine's Need to Respond to Cannabis Commercialization in the United States: A Commentary.

Candice M Bowling, Amy Y Hafez, Stanton A Glantz

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychoactive drugs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Candice M BowlingCenter for Tobacco Control Research and Education, Philip R. Lee Institute for Health Policy Studies, Department of Medicine, University of California, San Francisco , San Francisco, California, USA.
Amy Y HafezCenter for Tobacco Control Research and Education, Philip R. Lee Institute for Health Policy Studies, Department of Medicine, University of California, San Francisco , San Francisco, California, USA.
Stanton A GlantzCenter for Tobacco Control Research and Education, Philip R. Lee Institute for Health Policy Studies, Department of Medicine, University of California, San Francisco , San Francisco, California, USA.ORCID 0000-0003-4620-6672
University of California, San Francisco · US

Funding

Postdoctoral training in tobacco controlR25CA113710 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GLANTZ, STANTON ARNOLD · 2006 to 2015
$5.4M
Effect of Tobacco Advocacy at the State LevelR01DA043950 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI APOLLONIO, DOROTHY ELINOR · 2016 to 2020
$2.6M
Postdoctoral training in tobacco controlT32CA113710 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LING, PAMELA MAY · 2016 to 2020
$2.6M
NCI NIH HHS R25 CA113710NCI NIH HHS T32 CA113710NIDA NIH HHS R01 DA043950
6 · The paper itself

Abstract

Cannabis legalization has resulted in rapid commercialization, making this new market increasingly attractive to tobacco, alcohol and beverage, agricultural, and pharmaceutical multinational corporations, who are well positioned to capitalize on the synergy between cannabis and their products. The fact that cannabis remains a Schedule I drug under the Controlled Substances Act is inhibiting research, which consequently prevents evidence-based regulation of modern, more potent, engineered cannabis products and their use. Without a research exemption for legitimate studies of commercially available products, cannabis' Schedule I classification makes it very difficult to conduct medical and scientific research to inform policymaking and regulation. As corporate commercialization looms large, public health organizations need to engage the issue of rapid commercialization of cannabis products and press for evidence-based policies based on public health best practices.

Indexed as

CannabisHumansLegislation, DrugPolicy MakingPublic HealthTobacco UseUnited StatesCannabispublic policy

Identifiers

PMID32429772
PMCPMC7674246
OpenAlexW3028489361

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.